When Good Biology Isn't Enough: What the ZEUS Trial Teaches Us About Precision Medicine

Article

On July 31, 2026, Novo Nordisk reported that the Phase 3 ZEUS trial showed that despite significantly lowering IL-6–driven inflammation, ziltivekimab did not reduce cardiovascular events. At first glance, this appears to be a disappointing result for one of the most promising therapeutic targets in cardiovascular medicine. But perhaps the most important lesson is not about the failure of a drug—it is about the limitations of how we think about disease. For more than a decade, inflammation has been recognized as a major contributor to atherosclerosis. IL-6 emerged as a particularly attractive therapeutic target because it occupies a central position in the inflammatory cascade. Acting as one of the body's master communicators, IL-6 coordinates systemic responses to injury by stimulating production of acute-phase proteins such as C-reactive protein (CRP), activating immune cells, and orchestrating communication between tissues. The biological rationale was compelling, and ziltivekimab performed exactly as designed. It successfully inhibited IL-6 signaling and substantially lowered hsCRP, demonstrating robust target engagement. Yet patients did not experience fewer heart attacks, strokes, or cardiovascular deaths. This disconnect highlights one of the most important principles emerging in precision medicine: successful manipulation of a biological pathway does not necessarily translate into successful manipulation of a disease. The explanation likely lies in the remarkable redundancy of human biology. Unlike diseases in which IL-6 serves as the dominant pathological driver—such as giant cell arteritis, cytokine release syndrome, or Castleman disease—atherosclerosis is maintained by a complex and evolving network of interacting mechanisms. Lipid accumulation, endothelial dysfunction, macrophage activation, adaptive immunity, oxidative stress, thrombosis, and multiple cytokine pathways all contribute to plaque progression and instability. IL-6 is undoubtedly an important node within this network, but it is only one of many. This distinction is critical because biomarkers can be mistaken for mechanisms. CRP is one of the most reliable indicators of systemic inflammation precisely because IL-6 stimulates its production in the liver. Lowering CRP confirms that inflammatory signaling has been attenuated. It does not necessarily confirm that the biological processes responsible for plaque rupture have been fundamentally altered. In other words, CRP is an excellent reporter of inflammatory state, but not necessarily a surrogate for clinical benefit. None of this diminishes the importance of IL-6. In fact, IL-6 remains one of the most clinically validated cytokine targets in modern medicine. Blocking IL-6 has transformed the treatment of rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome associated with CAR-T cell therapy. These successes remind us that IL-6 is a powerful therapeutic target when it occupies a dominant position within the disease network. The ZEUS trial therefore should not be viewed as evidence that IL-6 biology is incorrect. Rather, it illustrates that disease biology is context dependent. The relative importance of a signaling pathway changes over time, differs among tissues, and varies from one patient to another. In advanced atherosclerosis, inhibiting IL-6 may simply leave sufficient parallel inflammatory pathways intact for disease progression to continue. This may ultimately be the broader lesson of precision medicine. The future is unlikely to be defined by discovering ever more molecular targets. Instead, it will depend on understanding which biological control nodes matter most, in which patients, and at what stage of disease. Therapeutic success will increasingly depend on matching interventions to dynamic biological states rather than static diagnostic labels. Negative clinical trials often move science forward as much as positive ones. ZEUS reminds us that biology operates as an interconnected network, not a collection of isolated pathways. It challenges us to think beyond individual molecules and toward a systems-based understanding of disease. In doing so, it reinforces the central promise of precision medicine—not simply to develop better drugs, but to better understand when, where, and why those drugs will make a meaningful difference.